Latest Canada News

Dataworks Group Limited reported a modest revenue increase and a reduced net loss for FY25, underpinned by major contract wins in Canada and Australia. The company is targeting cashflow positivity in the first half of FY26 following operational efficiencies and capital raises.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

MIXI Australia has secured majority voting power in PointsBet, pushing the takeover offer deadline to mid-September and setting the stage for full control.

Orthocell Ltd reported a record $9.23 million revenue for FY25, driven by strong sales of its nerve repair and dental products, alongside securing US FDA clearance for its flagship nerve repair device Remplir. The company is poised for accelerated growth as it expands its global commercial footprint.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

Bioxyne Limited reports a remarkable financial turnaround for FY2025, driven by a 217% revenue surge and its first significant profit, underpinned by expanded medicinal cannabis manufacturing and new supply contracts.

Aspermont Limited invites existing shareholders to participate in a $1.25 million Share Purchase Plan at a premium price, supporting its pivot to data-driven intelligence services and a strategic Rio Tinto partnership.

Spacetalk Ltd reports a successful FY25 transformation with revenue up 12%, losses narrowing by 57%, and a new software-led platform set to fuel scalable subscription growth.

Bathurst Resources reports a dip in FY25 earnings due to lower coal prices and operational challenges but pushes forward with key development projects Buller and Tenas, targeting production growth from FY29.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

Immuron Ltd reported a robust 49% increase in FY25 global sales, driven by strong Travelan® growth, while gearing up for a ProIBS launch and pivotal FDA meetings in 2025-26.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.